Gerd‐Rüdiger Burmester

Author

Also Known As

Ad-hoc Kommission Covid-19-Empfehlungen der Deutschen Gesellschaft für Rheumatologie, Burmester, Gerd-Rüdiger, Ch Specker, G BURMESTER, G Burmester, G R Burmester, G R Burmester., G. Burmester, G. R. Burmester, G.-R Burmester

230

Publications

17K

Citations

H-Index

106

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin German Rheumatism Research Centre Humboldt-Universität zu Berlin Berlin-Brandenburger Centrum für Regenerative Therapien University of Lübeck

About

Gerd‐Rüdiger Burmester is an author at Charité - Universitätsmedizin Berlin specializing in medicine, immunology, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	33	2.4K
2	Allergy	5	5	185
3	Health Sciences	3	3	165
4	Engineering	1	1	216
5	Applied Physiology	1	1	47

Gerd‐Rüdiger Burmester

108

Publications

14.7K

Citations

H-Index

Page 1

	Year	Citations
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative D. Aletaha, Tuhina Neogi, Alan J. Silman, Annals of the Rheumatic Diseases	2010	4.7K
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks Stanley Cohen, Paul Emery, Maria Greenwald, Arthritis & Rheumatism	2006	1.6K
Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo‐controlled trial Roy Fleischmann, Joy Schechtman, Ralph Bennett, Arthritis & Rheumatism	2003	392
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial Peter Nash, Bruce Kirkham, Masato Okada, The Lancet Rheumatoid DisorderRheumatologySpirit-p2 Phase 3Autoimmune DiseaseMedicine	2017	390
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus Tobias Alexander, Ramona Sarfert, Jens Klotsche, Annals of the Rheumatic Diseases	2015	352
Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus Caroline von Spee-Mayer, Elise Siegert, Dimas Abdirama, Annals of the Rheumatic Diseases	2015	325
Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system Tobias Alexander, Andreas Thiel, Oliver Rosen, Blood	2008	307
Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab Joachim Listing, Jörn Kekow, Bernhard Manger, Annals of the Rheumatic Diseases	2013	281
BMP2 initiates chondrogenic lineage development of adult human mesenchymal stem cells in high-density culture Bernhard M. Schmitt, Jochen Ringe, Thomas Häupl, Differentiation Regenerative MedicineDevelopmental BiologyHigh-density CultureBone Morphogenic ProteinMedicine	2003	232
Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial Gerd‐Rüdiger Burmester, Alan Kivitz, H. Küpper, Annals of the Rheumatic Diseases	2014	226

Page 1